Literature DB >> 11120980

Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers.

C K Naber1, M Steghafner, M Kinzig-Schippers, C Sauber, F Sörgel, H J Stahlberg, K G Naber.   

Abstract

Gatifloxacin (GTX), a new fluoroquinolone with extended antibacterial activity, is an interesting candidate for the treatment of chronic bacterial prostatitis (CBP). Besides the antibacterial spectrum, the concentrations in the target tissues and fluids are crucial for the treatment of CBP. Thus, it was of interest to investigate its penetration into prostatic and seminal fluid. GTX concentrations in plasma, urine, ejaculate, prostatic and seminal fluid, and sperm cells were determined by a high-performance liquid chromatography method after oral intake of a single 400-mg dose in 10 male Caucasian volunteers in the fasting state. Simultaneous application of the renal contrast agent iohexol was used to estimate the maximal possible contamination of ejaculate and prostatic and seminal fluid by urine. GTX was well tolerated. The means (standard deviations) for the following parameters were as indicated: time to maximum concentration of drug in serum, 1.66 (0. 91) h; maximum concentration of drug in serum, 2.90 (0.39) microg/ml; area under the concentration-time curve from 0 to 24 h, 25.65 microg. h/ml; and half life, 7.2 (0.90) h. Within 12 h about 50% of the drug was excreted unchanged into the urine. The mean renal clearance was 169 ml/min. The gatifloxacin concentrations in ejaculate, seminal fluid, and prostatic fluid were in the range of the corresponding plasma concentrations which were 1.92 (0.27) microg/ml at approximately the same time point (4 h after drug intake). The concentrations in sperm cells (0.195, 0.076, and 0.011 microg/ml) could be determined in three subjects. The good penetration into prostatic and seminal fluid, the good tolerance, and the previously reported broad antibacterial spectrum suggest that GTX may be a good alternative for the treatment of chronic bacterial prostatitis. Clinical studies should be performed to confirm this assumption.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120980      PMCID: PMC90275          DOI: 10.1128/AAC.45.1.293-297.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.

Authors:  R Wise; J M Andrews; J P Ashby; J Marshall
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

2.  Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.

Authors:  S Lober; S Ziege; M Rau; G Schreiber; A Mignot; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients.

Authors:  W Weidner; H G Schiefer; H Krauss; C Jantos; H J Friedrich; M Altmannsberger
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.

Authors:  K G Naber; F Sörgel; F Kees; H Schumacher; R Metz; H Grobecker
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

5.  Diffusion of antibiotics from plasma into prostatic fluid.

Authors:  D G Winningham; N J Nemoy; T A Stamey
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

6.  Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid.

Authors:  T A Stamey; E M Meares; D G Winningham
Journal:  J Urol       Date:  1970-02       Impact factor: 7.450

7.  Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg.

Authors:  K G Naber; F Sörgel; M Kinzig; D M Weigel
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

8.  Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.

Authors:  M Nakashima; T Uematsu; K Kosuge; H Kusajima; T Ooie; Y Masuda; R Ishida; H Uchida
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Concentrations of cefpodoxime in plasma, ejaculate and in prostatic fluid and adenoma tissue.

Authors:  K G Naber; M Kinzig; D Adam; F Sörgel; A H Bajorski; R Kiehn
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

10.  Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid.

Authors:  K G Naber; M Kinzig; F Sörgel; D Weigel
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

View more
  13 in total

1.  Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.

Authors:  Andrej Trampuz; Gerd Laifer; Markus Wenk; Zarko Rajacic; Werner Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men.

Authors:  F M E Wagenlehner; K G Naber
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

Review 3.  Prostatitis: the role of antibiotic treatment.

Authors:  F M E Wagenlehner; K G Naber
Journal:  World J Urol       Date:  2003-04-10       Impact factor: 4.226

4.  The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3.

Authors:  Koh Takeyama; Hiroaki Mitsuzawa; Chiaki Nishitani; Takeyuki Shimizu; Hitomi Sano; Yasuharu Kunishima; Satoshi Takahashi; Hiroshi Hotta; Masanori Matsukawa; Ken-Ichiro Shibata; Taiji Tsukamoto; Yoshio Kuroki
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

Review 5.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Authors:  Felipe K Hurtado; Benjamin Weber; Hartmut Derendorf; Guenther Hochhaus; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

7.  Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.

Authors:  Boubakar B Ba; Corinne Arpin; Céline Vidaillac; Arnaud Chausse; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves.

Authors:  M Raipuria; V K Dumka; H S Sandhu
Journal:  Vet Res Commun       Date:  2007-02-01       Impact factor: 2.816

9.  Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant Escherichia coli.

Authors:  Jharna Mandal; N Srinivas Acharya; D Buddhapriya; Subhash Chandra Parija
Journal:  Indian J Med Res       Date:  2012-11       Impact factor: 2.375

Review 10.  Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men.

Authors:  F M E Wagenlehner; K G Naber
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.